Francis A. Farraye, MD, MSc | Jonathan Kay, MD
Sharon Dudley-Brown, PhD, FNP-BBC, FAAN, FAANP | Tanya Golovanoff, PharmD, BCSCP


1. Welcome & Introduction
Jonathan Kay, MD

2. The Biosimilar Landscape in the US in 2021
Jonathan Kay, MD

3. Clinical Use of Biosimilars in Rheumatologic Disorders
Tanya Golovanoff, PharmD, BCSCP

4. Clinical use of Biosimilars in IBD
Francis A. Farraye, MD, MSc

5. Overcoming Barriers to Using Biosimilars in Clinical Practice
Sharon Dudley-Brown, PhD, FNP-BBC, FAAN, FAANP

Supported by an educational grant from Pfizer, Inc.

Jointly provided by Annenberg Center for Health Sciences at Eisenhower, Gi Health Foundation, Annual Rheumatology and Therapeutics Review for Organizations and Societies, Gastroenterology & Hepatology Advanced Practice Providers and Rheumatology Advanced Practice Providers.

This material is protected by copyright and other intellectual property laws. It may not be otherwise copied, printed, transmitted, or published unless explicit permission is obtained.
To request permission please contact us at tbd